Thurston Springer Miller Herd & Titak Inc. Has $968,000 Stake in Danaher Co. (NYSE:DHR)

Thurston Springer Miller Herd & Titak Inc. grew its holdings in Danaher Co. (NYSE:DHR) by 5.5% during the third quarter, Holdings Channel.com reports. The firm owned 3,481 shares of the conglomerate’s stock after acquiring an additional 180 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Danaher were worth $968,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Oak Thistle LLC acquired a new position in shares of Danaher during the second quarter worth approximately $363,000. HighPoint Advisor Group LLC bought a new position in Danaher in the 4th quarter valued at $2,614,000. Norden Group LLC acquired a new position in shares of Danaher during the first quarter valued at $4,151,000. Duality Advisers LP bought a new stake in Danaher during the 1st quarter worth about $5,573,000. Finally, Investment Research & Advisory Group Inc. bought a new position in shares of Danaher in the 1st quarter valued at about $1,186,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.5 %

Shares of Danaher stock opened at $270.33 on Monday. The firm has a market cap of $200.23 billion, a PE ratio of 45.82, a P/E/G ratio of 4.49 and a beta of 0.83. The business’s 50 day simple moving average is $270.31 and its 200 day simple moving average is $259.27. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the company earned $2.05 earnings per share. The firm’s revenue was down 2.9% compared to the same quarter last year. On average, analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio is 18.31%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Barclays raised their price objective on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. TD Cowen increased their target price on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Bank of America boosted their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Finally, Stephens assumed coverage on shares of Danaher in a report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price objective for the company. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Insider Activity

In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.